Abrocitinib in Elderly Eczema: Why Appetite and Nutrition Deserve Attention

Evidence summary only; systemic treatment decisions require a prescriber.

Beyond skin scores

A 2026 real-world study examined abrocitinib in elderly patients with moderate-to-severe atopic dermatitis and specifically tracked appetite changes. That outcome matters because reduced intake, weight loss, frailty and polypharmacy can have outsized consequences in older adults.

How to interpret effectiveness

Real-world improvement in EASI, itch or quality of life can show whether trial benefits translate into practice. However, without randomization, treatment selection and discontinuation influence results. People with serious baseline risks may never be offered the drug, making observed safety look better than it would in an unselected population.

Appetite findings need clinical context

Appetite can change because of medication, mood, infection, dental problems, gastrointestinal disease, altered taste, social isolation or relief from severe itch. A temporal association after starting treatment is not automatically proof of causation. Weight trends and other symptoms help determine significance.

JAK-inhibitor assessment

Abrocitinib requires drug-specific review of infection, thrombosis, cardiovascular and malignancy risks, laboratory monitoring and interacting medicines. Older adults may have less physiologic reserve and more competing risks. Do not stop suddenly or change the dose without the prescriber.

When to call

New persistent appetite loss, unintended weight loss, severe nausea, black stools, fever or marked weakness warrants medical assessment. Chest pain, sudden breathlessness, neurologic deficit or unilateral leg swelling is urgent.

Bottom line

The study broadens real-world evaluation beyond skin clearance. Geriatric eczema care should measure nutrition and function along with disease severity.

Related Dr. Arsy research

• Choosing an eczema moisturizer
• Eczema and sleep research guide
• Childhood eczema and school performance
• Comparing eczema treatments
• Targeted-therapy tapering evidence
• Recognizing eczema across skin tones

References

1. Abrocitinib in elderly adults real-world study
2. AAD systemic and phototherapy guideline
3. AAD topical therapy guideline
4. AAAAI/ACAAI GRADE guideline
5. Peer-led online self-management randomized trial
6. Emollient plus versus urea 10% trial
7. Upadacitinib in adults aged 60 years or older
8. Lebrikizumab in older adults real-world study
9. Tralokinumab in adults aged 70 years or older
10. JAK inhibitors in adults with cardiovascular comorbidity
11. Delgocitinib cream phase 2b trial
12. Ruxolitinib after topical treatment failure trial
13. Mometasone, crisaborole and tofacitinib pilot
14. CAN UpTIMISE after dupilumab study
15. DLLIM international 15,450-patient study
16. REZOLVE-AD phase 2b trial
17. Model-based meta-analysis of 77 studies
18. Targeted-therapy tapering systematic review
19. IL-4 receptor inhibitor meta-analysis
20. Dupilumab SOLO phase 3 trials
21. Tralokinumab ECZTRA 1 and 2 trials
22. Lebrikizumab ADvocate trials
23. Upadacitinib Measure Up trials
24. Abrocitinib JADE MONO-1 trial

Citations do not imply endorsement of #003.